Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665728 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects
A Phase 2 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02665728: Completed Phase 2 study, sponsored by Braintree Laboratories.
NCT02665728 is a Phase 2 study that has completed, run by Braintree Laboratories. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02665728, a Phase 2 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of BLI400 laxative in constipated adolescent subjects.
Primary Outcome
Overall treatment response is defined as weekly response in at least 2 out of 4 weeks. Weekly response is defined as greater than or equal to 3 spontaneous bowel movements during a week.
Interventions
- DRUG BLI400 Laxative
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT02665728 record still lists
NCT02665728 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which BLI400 Laxative is the first listed.
NCT02665728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02665728 about?
NCT02665728 is a clinical study titled "A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects". The objective of this study is to evaluate the safety and efficacy of BLI400 laxative in constipated adolescent subjects.
What is the current status of trial NCT02665728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2015-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02665728?
The interventions under investigation include: BLI400 Laxative (DRUG).
Who is sponsoring clinical trial NCT02665728?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02665728's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia